Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial (COLSTAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04472611
Recruitment Status : Completed
First Posted : July 15, 2020
Last Update Posted : May 16, 2022
Information provided by (Responsible Party):
Yale University

Brief Summary:
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
Actual Study Start Date : October 30, 2020
Actual Primary Completion Date : March 30, 2022
Actual Study Completion Date : May 12, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Standard of Care (SOC) and Colchicine+Rosuvastatin
Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin
Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization

No Intervention: Standard of care (SOC)
Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization

Primary Outcome Measures :
  1. COVID 19 Severity [ Time Frame: 30 Days ]
    As defined by World Health Organization Ordinal Scale, which ranges from 1 to 8. Severity of COVID measured by WHO Scores 5-8: Defined as 5= Hospitalized requiring including CPAP, face mask, high flow nasal cannula (Excludes regular nasal cannula) 6= Hospitalized requiring intubation and mechanical ventilation 7= Hospitalized requiring mechanical ventilation and additional organ support (vasopressors, renal replacement therapy, ECMO) 8= Death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria 1.18 years or older and confirmed SARS-CoV-2 infection by RT-PCR 2. Patient is admitted to the floor (non-ICU) within 48 hours of hospital admission 3. The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided witnessed (by 2 independent members of the health care team) oral informed consent, or a photograph of the signed informed consent approved by the Institutional Review Board (IRB)

Exclusion Criteria:

  1. Known pregnancy or nursing mothers
  2. Known allergy to statins or colchicine
  3. Patient is on chronic colchicine or oral corticosteroid treatment
  4. Acute liver disease defined by elevated transaminases (AST/ALT > 3x ULN)
  5. Severe chronic kidney disease defined as glomerular filtration rate (GFR) < 30mL/min1.73 m2
  6. Severe QTc prolongation (>500ms narrow QRS<120ms and >550ms for wide QRS>120)
  7. Presents with severe disease on admission (WHO ordinal scale of clinical improvement scores 5-8)
  8. Rhabdomyolysis or CPK > 5x ULN
  9. Thrombocytopenia defined as platelet count < 50,000 / mm3
  10. Leukopenia defined as white blood cell count < 3000 ml
  11. Severe anemia defined as Hemoglobin value <8 g/100ml
  12. Participation in any other clinical trial of an experimental treatment for COVID-19

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04472611

Layout table for location information
United States, Connecticut
Bridgeport Hospital
Bridgeport, Connecticut, United States, 06610
Greenwich Hospital
Greenwich, Connecticut, United States, 06807
Yale New Haven Hosptial System
New Haven, Connecticut, United States, 06512
Lawrence & Memorial Hospital
New London, Connecticut, United States, 06320
Sponsors and Collaborators
Yale University
Layout table for investigator information
Principal Investigator: Alexandra Lansky, MD Yale University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yale University Identifier: NCT04472611    
Other Study ID Numbers: 2000027950
First Posted: July 15, 2020    Key Record Dates
Last Update Posted: May 16, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yale University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antineoplastic Agents